What's up at Im­muno­core?; Pfiz­er nabs a key 'break­through'; Adap­ti­m­mune rais­es $100M

→ What’s up at Im­muno­core? Van­tage is re­port­ing that Im­muno­core’s chief strat­e­gy of­fi­cer Kevin Po­jasek is out, mark­ing the lat­est in a long line of C-suite de­par­ture for the com­pa­ny. CEO Eliot Forster was first to de­part, even though he was en­gaged in try­ing to raise an­oth­er mas­sive round for the com­pa­ny. Then there was a long string of ex­its, which have all been put down to per­son­al rea­sons.

→ Adap­ti­m­mune $ADAP, a sis­ter com­pa­ny of sorts to Im­muno­core, says it just raised $100 mil­lion. The TCR biotech ex­pert, al­lied with GSK, sold shares to Ma­trix Cap­i­tal Man­age­ment Com­pa­ny, New En­ter­prise As­so­ciates and Syn­cona Port­fo­lio Lim­it­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER